碳离子对比基于光子的立体性废除辐射疗法,用于患有冠状黑色素瘤的患者
Jina Kim1, Masaru Wakatsuki2, Shuri Aoki2,3
1Department of Radiation Oncology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Advances in radiation oncology
|November 17, 2025
概括
碳离子辐射疗法 (CIRT) 与立体性废除性辐射疗法 (SABR) 相比,在胆管黑色素瘤中提供了更好的治疗结果. 在这组患者中,CIRT显示出更好的无进展生存率,局部控制和眼睛/视力保存.
科学领域:
- 眼科医生 眼科 眼科
- 辐射瘤学 辐射瘤学
- 医学物理 医学物理
背景情况:
- 冠状黑色素瘤是一种罕见的眼内恶性瘤.
- 治疗方案包括放射治疗,其中碳离子辐射疗法 (CIRT) 和基于光子的立体性废除性辐射疗法 (SABR) 是先进的技术.
- 缺少CIRT和SABR之间的直接比较结果数据,用于冠状腺黑色素瘤.
研究的目的:
- 为了比较碳离子辐射疗法 (CIRT) 与基于光子的立体性废除性辐射疗法 (SABR) 的治疗结果,在患有冠状腺黑色素瘤的患者中.
- 评估CIRT和SABR在治疗局部胆膜黑色素瘤方面的疗效和安全性.
主要方法:
- 这是一项回顾性研究,包括在2001年至2021年期间治疗的346名局部胆管黑色素瘤患者.
- 患者接受了CIRT (平均70 Gy在14 Gy/分数中) 或SABR (平均60 Gy在15 Gy/分数中).
- 倾向性得分匹配 (PSM) 用于平衡基线特征;无进展生存 (PFS) 是主要终点.
主要成果:
- 在PSM后,5年PFS显著高于CIRT (69.0%) 与SABR (56.5%) 相比 (P=.024).
- 在CIRT中,局部衰竭 (5.6%与13.4%,P=.025) 和核化 (8.5%与24.2%,P<.001) 的比率显著降低.
- 在CIRT组 (P=.005) 中,视力敏度的保存优越 (P=.005).
结论:
- 碳离子辐射疗法 (CIRT) 优于以光子为基础的立体性废除性辐射疗法 (SABR) 治疗胆管黑色素瘤.
- CIRT显示了改善的无进展生存率,局部控制和眼睛/视觉保存.
- 对于被诊断为冠状腺黑色素瘤的患者来说,CIRT代表了一个更有效的治疗选择.
更多相关视频
相关概念视频
Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


